Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.
Shiba-Ishii A, Johnson TW, Dagogo-Jack I, Mino-Kenudson M, Johnson TR, Wei P, Weinrich SL, McTigue MA, Walcott MA, Nguyen-Phuong L, Dionne K, Acker A, Kiedrowski LA, Do A, Peterson JL, Barth JL, Yeap BY, Gainor JF, Lin JJ, Yoda S, Hata AN
Nat Cancer. 2022 Jun 20. pii: 10.1038/s43018-022-00399-6. doi: 10.1038/s43018-022-00399-6. PubMed Article
Shiba-Ishii A, Johnson TW, Dagogo-Jack I, Mino-Kenudson M, Johnson TR, Wei P, Weinrich SL, McTigue MA, Walcott MA, Nguyen-Phuong L, Dionne K, Acker A, Kiedrowski LA, Do A, Peterson JL, Barth JL, Yeap BY, Gainor JF, Lin JJ, Yoda S, Hata AN
Nat Cancer. 2022 Jun 20. pii: 10.1038/s43018-022-00399-6. doi: 10.1038/s43018-022-00399-6. PubMed Article
Plasmids from Article
| ID | Plasmid | Purpose |
|---|---|---|
| 183832 | pLenti-EML4-ALK variant 3a I1171N | Express EML4-ALK fusion variant 3a (E6a;A20) harboring ALK I1171N mutation in mammalian cells |
| 183833 | pLenti-EML4-ALK variant 3a I1171N/D1203N | Express EML4-ALK fusion variant 3a (E6a;A20) harboring ALK I1171N/D1203N mutation in mammalian cells |